(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.61%) $83.34
(-1.16%) $1.619
(0.03%) $2 347.80
(0.93%) $27.51
(0.23%) $924.20
(-0.06%) $0.934
(-0.10%) $11.01
(-0.09%) $0.800
(0.00%) $92.17
Live Chart Being Loaded With Signals
AXIM Biotechnologies, Inc. develops and sells diagnostic healthcare solutions in the areas of SARS-CoV-2, eye health, and oncology. The company is developing rapid diagnostic tests, which measure the levels of functional neutralizing antibodies that prevent SARS-CoV-2 from attaching to human cells; serological diagnostic test, which detect neutralizing antibodies that measure adaptive immune response to the SARS-CoV-2 virus; and tests for management of COVID-19 Patients to detect biomarkers related to inflammation...
Stats | |
---|---|
本日の出来高 | 126 525 |
平均出来高 | 547 284 |
時価総額 | 3.81M |
EPS | $0.000690 ( 2023-11-20 ) |
次の収益日 | ( $0 ) 2024-05-22 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.340 |
ATR14 | $0.00100 (7.30%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-15 | Huemoeller John Walter Ii | Buy | 250 000 | Convertible Note |
2024-03-15 | Valencia Catalina | Buy | 7 837 500 | Convertible Note |
2024-03-15 | Schroeder Blake | Buy | 35 000 | Convertible Note |
2024-03-15 | Cunningham Robert L | Buy | 35 000 | Convertible Note |
2024-03-15 | Scott Timothy Richard | Buy | 35 000 | Convertible Note |
INSIDER POWER |
---|
100.00 |
Last 56 transactions |
Buy: 36 148 017 | Sell: 23 000 000 |
AXIM Biotechnologies, 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
AXIM Biotechnologies, 財務諸表
Annual | 2023 |
収益: | $39 518.00 |
総利益: | $-387 501 (-980.57 %) |
EPS: | $-0.0354 |
FY | 2023 |
収益: | $39 518.00 |
総利益: | $-387 501 (-980.57 %) |
EPS: | $-0.0354 |
FY | 2022 |
収益: | $8 875.00 |
総利益: | $-417 251 (-4 701.42 %) |
EPS: | $-0.0360 |
FY | 2021 |
収益: | $60 460.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-0.120 |
Financial Reports:
No articles found.
AXIM Biotechnologies,
AXIM Biotechnologies, Inc. develops and sells diagnostic healthcare solutions in the areas of SARS-CoV-2, eye health, and oncology. The company is developing rapid diagnostic tests, which measure the levels of functional neutralizing antibodies that prevent SARS-CoV-2 from attaching to human cells; serological diagnostic test, which detect neutralizing antibodies that measure adaptive immune response to the SARS-CoV-2 virus; and tests for management of COVID-19 Patients to detect biomarkers related to inflammation. It is also developing rapid quantitative tear tests for Matrix metalloproteinase-9, an inflammatory biomarker for dry eye disease; SBI-183, an anti-metastatic compound suppressing tumor cell growth and blocking metastasis; and SPX-1009, an anti-metastatic treatment to measure levels of quiescin sulfhydryl oxidase I. The company was formerly known as Axim International Inc. and changed its name to AXIM Biotechnologies, Inc. in July 2014. AXIM Biotechnologies, Inc. was incorporated in 2010 and is based in San Diego, California.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。